Skip to content

Ron Bentsur, Chairman & CEO at Nuvectis Pharma, bought NVCT on Jun 30, 2026

Data as of Oct 16

▲ BUY$250K12,500 shares at $20.00Ron Bentsur Chairman & CEONVCT Nuvectis Pharma, Inc.
Watch NVCT
Traded
Jun 30, 2026
Disclosed
Jul 1, 2026
Filed
1 day after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Ron Bentsur, Chairman & CEO at Nuvectis Pharma, bought NVCT on Jun 30, 2026TRADEDDISCLOSED
NVCTSimilar stocks (XLV — its sector index fund), rebased to NVCT's price on the disclosure day
NVCT since disclosure
−4.7%
Similar stocks (XLV) since disclosure
+10.8%
XLV — its sector index fund

Change in closing price from Jul 1, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

See every trade on NVCT →